The DOI matches its Crossref record.
Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis
Open accessAbstract
Leflunomide has been reported as an alternative therapy in sarcoidosis. However, the published data are limited. We performed a retrospective chart review of the tolerance and effects of leflunomide therapy in patients with sarcoidosis. 76 patients were included. The most common reasons for initiation were progression of disease or failure of other immunomodulator therapy. Side-effects attributable to leflunomide were noted in 34% of subjects, prompting discontinuation in 17%. The lungs were a target of therapy in 33 (44%) and extrapulmonary organs were a target in 45 (59%). The mean± sd change in forced vital capacity in the 6 months prior to leflunomide was −0.1±0.3 L, and it was +0.09±0.3 L in the following 6 months (p=0.01). For extrapulmonary target organ response, 51% had a good response and 32% a partial response. The median corticosteroid dose at initiation was 10 mg (interquartile range 5–20) mg at baseline, and 0 (0–10) mg at the 6-month follow-up (p<0.001). Leflunomide is a viable alternative agent for pulmonary and extrapulmonary sarcoidosis. Leflunomide appears to facilitate reduction of steroid dose and can be considered as monotherapy or as add-on therapy in cases of progressive disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 25
- 10.1074/jbc.273.34.21682 · DOI · Paper page
- Cohen, 2003, Leflunomide, Int J Clin Pract, 57, 115, 10.1111/j.1742-1241.2003.tb10439.x · doi:10.1111/j.1742-1241.2003.tb10439.x
- 10.2165/00063030-199912040-00007 · DOI
- 10.3949/ccjm.71.2.88 · DOI
- 10.1164/ajrccm.160.2.ats4-99 · DOI · Paper page
- Baughman, 2004, Leflunomide for chronic sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 21, 43
- Judson, 1999, Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A case control etiologic study of sarcoidosis, Sarcoidosis Vasc Diffuse Lung Dis, 16, 75
- 10.1378/chest.130.1.30 · doi:10.1378/chest.130.1.30
- Stoller, 1993, Trial of standard versus modified expiration to achieve end-of-test spirometry criteria, Am Rev Respir Dis, 148, 275, 10.1164/ajrccm/148.2.275 · DOI
- 10.1016/j.ccm.2008.03.012 · DOI · Paper page
- 10.1055/s-0030-1262218 · doi:10.1055/s-0030-1262218
- Sweiss, 2010, Sarcoidosis requiring systemic steroid: why not a steroid-sparing regimen up-front?, Sarcoidosis Vasc Diffuse Lung Dis, 27, 3
- Baughman, 2000, Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial, Sarcoidosis Vasc Diffuse Lung Dis, 17, 60
- 10.1378/chest.125.3.997 · DOI · Paper page
- 10.1016/j.rmed.2009.12.009 · DOI · Paper page
- 10.1093/rheumatology/keg156 · doi:10.1093/rheumatology/keg156
- Pinto, 2006, Leflunomide in clinical practice, Acta Reumatol Port, 31, 215
- 10.1111/j.1445-5994.2008.01792.x · doi:10.1111/j.1445-5994.2008.01792.x
- 10.2165/11532390-000000000-00000 · doi:10.2165/11532390-000000000-00000
- 10.1136/ard.61.1.42 · doi:10.1136/ard.61.1.42
- Bettembourg-Brault, 2006, Leflunomide in rheumatoid arthritis in daily practice: treatment discontinuation rates in comparison with other DMARDs, Clin Exp Rheumatol, 24, 168
- 10.1007/s10067-010-1425-3 · DOI
- 10.2169/internalmedicine.45.1455 · doi:10.2169/internalmedicine.45.1455
- 10.1093/rheumatology/kep052 · doi:10.1093/rheumatology/kep052
- 10.2165/11316650-000000000-00000 · DOI
Cited by
Valeyre, D., Prasse, A., Nunes, H., Uzunhan, Y., Brillet, P.-Y., & Müller-Quernheim, J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60680-7 · Cited by 1,087
ERS clinical practice guidelines on treatment of sarcoidosis
Baughman, R. P., Valeyre, D., Korsten, P., Mathioudakis, A. G., Wuyts, W. A., Wells, A., Rottoli, P., Nunes, H., Lower, E. E., Judson, M. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04079-2020 · Cited by 629
Self-citationDiagnosis and Treatment of Pulmonary Sarcoidosis: A Review
Belperio, J. A., Shaikh, F., Abtin, F. G., Fishbein, M. C., Weigt, S. S., Saggar, R., & Lynch, J. P. (2022) · JAMA · doi:10.1001/jama.2022.1570 · Cited by 191
Kidney manifestations of sarcoidosis.
Bonella, F., DM Vorselaars, A., & Wilde, B. (2024) · Journal of autoimmunity · doi:10.1016/j.jaut.2024.103207 · Cited by 32
Metadata
- Authors
- Sahoo, D. H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J. G., Lazar, C. A., Chapman, J. T., & Culver, D. A.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2011-05-12
- Volume
- 38
- Issue
- 5
- Pages
- 1145-1150
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2104680378
- Cited by
- 173
- References
- 0
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. https://app.cochat.ai/papers/10.1183/09031936.00195010
- The paper
- Sahoo, D. H., Bandyopadhyay, D., Xu, M., Pearson, K., Parambil, J. G., Lazar, C. A., Chapman, J. T., & Culver, D. A. (2011). Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00195010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.